Asia Pacific Next Generation Sequencing (NGS) Market Size, Share, and COVID-19 Impact Analysis, By Technology (WGS, Whole Exome Sequencing, Targeted Sequencing & Resequencing, and Others), By Application (Oncology, Clinical Investigation, Reproductive Health, HLA Typing/Immune System Monitoring, Metagenomics, Epidemiology & Drug Development, Agrigenomics & Forensics, and Consumer Genomics), and Asia Pacific Next Generation Sequencing (NGS) Market Insights, Industry Trend, Forecasts to 2035.

Asia Pacific Next Generation Sequencing (NGS) Market Insights Forecasts to 2035

• The Asia Pacific Next Generation Sequencing (NGS) Market Size was estimated at USD 3.0 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 19.51% from 2025 To 2035
• The Asia Pacific Next Generation Sequencing (NGS) Market Size is Expected to Reach USD 21.3 Billion By 2035

The Asia Pacific Next Generation Sequencing (NGS) Market Size is Anticipated to reach USD 21.3 Billion By 2035, Growing at a CAGR of 19.51% from 2025 to 2035. The growing prevalence of chronic diseases, advancements in genomics, and demand for personalized medicine & precision oncology are driving the next generation sequencing (NGS) market in the Asia Pacific region.

Market Overview

The Asia Pacific next generation sequencing (NGS) market refers to the industry fueled by the demand for faster, more affordable, and accurate DNA sequencing technologies. Next-generation sequencing (NGS) is a massively parallel sequencing of DNA and RNA, allowing researchers and clinicians to analyze entire genomes or targeted regions with unprecedented speed and precision. Identification of genetic mutations & biomarkers, enabling targeted therapies and advanced precision medicine initiatives, is driving the NGS market. Further, the expanding adoption of NGS technologies in clinical diagnostics, owing to the rapid result time and faster processing, is contributing to driving the market growth for next generation sequencing.

Report Coverage

This research report categorizes the market for the Asia Pacific next generation sequencing (NGS) market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Asia Pacific next generation sequencing (NGS) market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Asia Pacific next generation sequencing (NGS) market.

Driving Factors

The growing prevalence of chronic disease has driven the demand for genomic research by using NGS technology, for improving the understanding of diseases and personalized healthcare, driving the market growth. The advancements in genomics for understanding genetic variations, gene expression, epigenetic modifications, and microbial diversity are propelling the market growth. The implementation of NGS for cancer patients, empowering treatment decision making, thereby contributing to driving the market growth.

Restraining Factors

The complex data interpretation & management, ethical & legal concerns, and lack of skilled personnel availability are challenging the market. The increased initial investment cost for developing advanced sequencing technology, limiting its adoption in smaller labs and academic institutions, is restraining the market.

Market Segmentation

The Asia Pacific next generation sequencing (NGS) market share is classified into technology and application.

• The targeted sequencing & resequencing segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific next generation sequencing (NGS) market is segmented by technology into WGS, whole exome sequencing, targeted sequencing & resequencing, and others. Among these, the targeted sequencing & resequencing segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. Targeted sequencing offers a cost-effective way of examining specific genes or regions, while resequencing aids in identifying the variations between samples and references. Targeted sequencing services offered by many companies are driving the market growth.

• The oncology segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific next generation sequencing (NGS) market is segmented by application into oncology, clinical investigation, reproductive health, HLA typing/immune system monitoring, metagenomics, epidemiology & drug development, agrigenomics & forensics, and consumer genomics. Among these, the oncology segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. NGS is increasingly applied in cancer genomic research and has been adopted in clinical oncology for advancing personalized treatment for cancer. The use of the latest technology for enabling a better understanding of cancer and tumor cell mechanics is driving the market growth in the oncology segment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Asia Pacific next generation sequencing (NGS) market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Agilent Technologies, Inc.
• ThermoFisher Scientific, Inc.
• QIAGEN
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• BGI (A subsidiary of BGI Group)
• Oxford Nanopore Technologies plc.
• Others

Recent Developments:

• In May 2024, National Health Insurance (NHI) officially integrated next-generation sequencing (NGS) testing into its coverage benefits. According to the National Health Insurance Administration (NHIA), this measure is estimated to benefit over 20,000 cancer patients per year, with a budget of approximately NT$300 million.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Asia Pacific, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Asia Pacific Next Generation Sequencing (NGS) Market based on the below-mentioned segments

Asia Pacific Next Generation Sequencing (NGS) Market, By Technology

• WGS
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing
• Others

Asia Pacific Next Generation Sequencing (NGS) Market, By Application

• Oncology
• Clinical Investigation
• Reproductive Health
• HLA Typing/Immune System Monitoring
• Metagenomics
• Epidemiology & Drug Development
• Agrigenomics & Forensics
• Consumer Genomics